Human(ized) monoclonal antibodies in atopic patients - state of the art
CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, cilt.45, ss.195-201, 2020 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 45
- Basım Tarihi: 2020
- Doi Numarası: 10.5114/ceji.2020.97909
- Dergi Adı: CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, EMBASE, Directory of Open Access Journals
- Sayfa Sayıları: ss.195-201
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Kütahya Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Asthma is an important chronic disease affecting a lot of people worldwide. Treatment options for asthma like biological agents are being developed more frequently nowadays. Despite a lot of treatment options, some patients still remain symptomatic. As more and more practitioners choose treatment with biologic agents as a convenient way of therapy, biologic agents and other valuable methods must be discovered in order to cope with a growing number of treatment agents. This manuscript emphasizes on new generation monoclonal human(ized) antibodies in asthmatics and off-label use. The first developed biologic agent is the anti-immunoglobulin E monoclonal antibody called omalizumab. Currently it is an approved treatment option for asthma.